Another explored inhibitor is eculizumab, an anti-C5 MoAb known for revolutionizing the therapeutic landscape of PNH, another form of complement-mediated, DAT-negative hemolytic anemia (Figure 3) (161). Here, SLC6A3 is linked to paroxysmal nocturnal hemoglobinuria.